To the Editor We read with interest the article by Jabbour et al1 regarding their phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer (NSCLC). This nonrandomized controlled trial highlights that combined treatment for stage III NSCLC is safe and tolerable, with promising progression-free survival; however, we have some questions.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zhang J, Fu J, Zhang G. Assessing Expression of PD-L1 in Tumor-Associated Macrophages. JAMA Oncol. 2020;6(10):1634. doi:10.1001/jamaoncol.2020.2698
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: